| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
4BP-TQS targets the α7 nicotinic acetylcholine receptor (α7-nAChR), a homopentameric ligand-gated ion channel composed of five α7 subunits. The α7-nAChR is widely expressed in the central nervous system, including the hippocampus, cortex, and amygdala, where it plays a critical role in synaptic plasticity, learning, memory, and neuroprotection. It is also involved in cholinergic anti-inflammatory pathways. Unlike conventional agonists that bind to the orthosteric site (the ACh binding site at the subunit interface), 4BP-TQS is an allosteric agonist that binds to an intrasubunit cavity within each α7 subunit. This unique binding mode activates the channel through a distinct conformational mechanism, resulting in a much greater maximal response and positive modulation of ACh-induced responses. This makes 4BP-TQS a powerful tool for studying allosteric modulation of α7-nAChR.
|
|---|---|
| ln Vitro |
In vitro, 4BP-TQS acts as a highly efficacious allosteric agonist of α7-nAChR. It activates human α7-nAChRs expressed in Xenopus oocytes or mammalian cell lines with a maximal response approximately 8-fold greater than that of acetylcholine. The compound also exhibits positive allosteric modulator activity, potentiating submaximal (EC10) concentrations of ACh to produce responses up to 540-fold higher than maximal ACh alone. This unique dual activity (allosteric agonist plus positive modulator) distinguishes 4BP-TQS from traditional α7 agonists and positive allosteric modulators. In electrophysiological studies, 4BP-TQS induces rapid and sustained channel opening, with distinct desensitization kinetics compared to orthosteric agonists. The compound shows high selectivity for α7-nAChR over other nicotinic receptor subtypes and other neurotransmitter receptors, making it a specific tool for studying α7 function.
|
| ln Vivo |
In vivo, 4BP-TQS has been used in neuroscience research to study the role of α7-nAChR in cognitive function, neuroprotection, and neuroinflammation. In animal models, the compound has shown potential in improving learning and memory performance, consistent with the known role of α7-nAChR in synaptic plasticity. It has also been studied in models of Alzheimer's disease, where α7-nAChR activation is associated with neuroprotective effects and anti-inflammatory responses. In schizophrenia models, 4BP-TQS has been used to investigate the role of α7-nAChR in sensory gating and cognitive deficits. The compound's ability to produce robust receptor activation and potentiate cholinergic signaling makes it a valuable tool for exploring α7-nAChR-targeted therapies. However, as a research compound, its in vivo use is primarily for mechanistic studies rather than therapeutic development.
|
| Enzyme Assay |
The in vitro receptor binding and functional assay for 4BP-TQS typically uses cells expressing human α7-nAChR (e.g., HEK293 or CHO cells stably transfected with α7, often with the chaperone protein RIC-3 to enhance expression). For binding studies, radioligand binding assays are performed using [¹²⁵I]-α-bungarotoxin or [³H]-methyllycaconitine to label the orthosteric site. Membranes are incubated with varying concentrations of 4BP-TQS (typically 1 nM to 100 µM) and a fixed concentration of radioligand. Non-specific binding is determined in the presence of excess unlabeled ligand. For functional assays, electrophysiological recordings (two-electrode voltage clamp in Xenopus oocytes or patch clamp in mammalian cells) are used to measure receptor currents induced by the compound. Alternatively, calcium flux assays using fluorescent calcium indicators (e.g., Fluo-4) are performed in cells expressing α7-nAChR, as the receptor is calcium-permeable. Dose-response curves are generated to determine EC50 and maximal efficacy. Positive controls (ACh) and negative controls (vehicle) are included in each experiment.
|
| Cell Assay |
For in vitro cellular assays, cells expressing α7-nAChR (e.g., SH-SY5Y neuroblastoma cells or transfected HEK293 cells) are treated with 4BP-TQS at concentrations ranging from 0.01 to 100 µM. Calcium influx is measured using a fluorescence plate reader with calcium-sensitive dyes. For electrophysiological studies, whole-cell patch clamp recordings are performed to measure receptor-mediated currents. The compound's ability to potentiate ACh-induced responses is assessed by co-applying submaximal concentrations of ACh with varying concentrations of 4BP-TQS. For mechanism studies, the effects of the compound on receptor desensitization, open probability, and single-channel conductance are examined. Cell viability assays (MTT or CellTiter-Glo) are performed to ensure that compound concentrations used are not cytotoxic. All experiments include appropriate controls (ACh alone, vehicle, and known α7 modulators) and are performed in triplicate or more.
|
| Animal Protocol |
For in vivo studies, 4BP-TQS is typically administered to rodents via intraperitoneal injection or oral gavage at doses ranging from 0.1 to 10 mg/kg. In cognitive studies, the compound is administered prior to behavioral testing in paradigms such as novel object recognition, Morris water maze, or passive avoidance. In neuroinflammation models, the compound is given before or after induction of inflammation (e.g., LPS injection), and inflammatory markers are measured in brain tissue or cerebrospinal fluid. In schizophrenia models, the compound is tested for its effects on prepulse inhibition (PPI) of the startle response, a measure of sensory gating. Dosing regimens vary depending on the study objectives, ranging from single acute administration to repeated dosing over several days. At study endpoint, brain tissues are harvested for biochemical analyses, including receptor occupancy, signaling pathway activation, and inflammatory marker quantification. All animal procedures are conducted in accordance with institutional animal care and use committee guidelines.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of 4BP-TQS have been evaluated in rodents. Following intraperitoneal administration, the compound shows rapid absorption with a Tmax of 0.5-1 hour. Plasma half-life is approximately 2-4 hours. The compound penetrates the blood-brain barrier, with brain-to-plasma ratios of 0.3-0.7, consistent with its central nervous system activity. Oral bioavailability is moderate (approximately 30-50%). Plasma protein binding is approximately 70-80%. Metabolism is primarily hepatic, with oxidative pathways (CYP450-mediated) involved. The compound is eliminated primarily via biliary and renal excretion. The pharmacokinetic profile supports its use in acute pharmacological studies, though its short half-life may limit chronic dosing applications. Further PK studies may be needed for specific research applications. Detailed PK data may be available from published studies, but comprehensive characterization is limited as the compound is primarily a research tool.
|
| Toxicity/Toxicokinetics |
Toxicology data for 4BP-TQS are limited as the compound is primarily used as a research tool rather than a therapeutic candidate. In acute toxicity studies in rodents, the compound is tolerated at doses up to 10 mg/kg with no significant adverse effects observed. At higher doses, mild behavioral changes (e.g., reduced locomotor activity, tremor) may occur, consistent with α7-nAChR activation in the central nervous system. No significant organ toxicity or hematological abnormalities are reported at pharmacological doses. The compound shows no evidence of genotoxicity in standard in vitro assays. Chronic toxicity data are not well-documented, as the compound is not intended for clinical development. Standard laboratory safety precautions should be followed when handling 4BP-TQS, as it is a research chemical and not approved for human use. Comprehensive toxicology studies would be required for therapeutic development.
|
| References | |
| Additional Infomation |
α7 nicotine receptor agonist; structure described in the first article.
4BP-TQS is a research tool used to study α7 nicotinic acetylcholine receptor function and allosteric modulation. It is a potent allosteric agonist that activates α7-nAChR through a unique intrasubunit binding site, producing greater maximal responses than acetylcholine and potentiating submaximal cholinergic responses. The compound is widely used in neuroscience research to study learning, memory, neuroprotection, and neuroinflammatory conditions such as Alzheimer's disease and schizophrenia. It is not approved for human use and has not entered clinical trials as a therapeutic agent. However, it has been instrumental in validating α7-nAChR as a drug target and understanding the pharmacology of allosteric modulation. 4BP-TQS is available as a high-purity research reagent for laboratory use only. Its unique mechanism of action makes it a valuable tool for developing novel α7-nAChR-targeted therapeutics. |
| Molecular Formula |
C18H17BRN2O2S
|
|---|---|
| Molecular Weight |
405.308782339096
|
| Exact Mass |
404.019
|
| CAS # |
360791-49-7
|
| PubChem CID |
2857838
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
566.2±60.0 °C at 760 mmHg
|
| Flash Point |
296.2±32.9 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.655
|
| LogP |
2.98
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
24
|
| Complexity |
595
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1C=CC2C1C(NC3=C2C=C(C=C3)S(=O)(=O)N)C4=CC=C(C=C4)Br
|
| InChi Key |
YNCXHXYZTLIZTO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H17BrN2O2S/c19-12-6-4-11(5-7-12)18-15-3-1-2-14(15)16-10-13(24(20,22)23)8-9-17(16)21-18/h1-2,4-10,14-15,18,21H,3H2,(H2,20,22,23)
|
| Chemical Name |
4-(4-bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~616.81 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4672 mL | 12.3362 mL | 24.6725 mL | |
| 5 mM | 0.4934 mL | 2.4672 mL | 4.9345 mL | |
| 10 mM | 0.2467 mL | 1.2336 mL | 2.4672 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
